Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + trametinib
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel + trametinib is a combination of two pharmaceutical agents used in oncology. Docetaxel is a taxoid antineoplastic agent that promotes the assembly and stabilization of microtubules by binding to the β-subunit of tubulin, thereby inhibiting cell division and inducing cancer cell death[5][6]. Trametinib is a kinase inhibitor that selectively inhibits MEK1 and MEK2, key components in the MAPK/ERK signaling pathway involved in cell proliferation; it blocks abnormal protein signaling that drives cancer growth[1][4]. This combination has been studied for use in cancers with specific genetic mutations such as KRAS-mutant non-small-cell lung cancer (NSCLC), where both drugs are administered together to target different mechanisms essential for tumor survival and proliferation[8].
- Brand names
- MekinistTaxotere
- Other names
- combination trametinib and docetaxel
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + trametinib.